Производство металлоконструкций | Длительность: 4:38 | Просмотры: 573
Автор: ДК-Спецстрой | Просмотров: 573 | Длительность: 4:38
4:38
573
ДК-Спецстрой
28 июн. 2024 г. · A Study of Longer Interval of IVT IBI302 in Subjects With nAMD ClinicalTrials.gov ID NCT05403749 Sponsor Innovent Biologics (Suzhou) Co. Ltd. Information provided by Innovent … 25 мар. 2024 г. · The multicenter, randomized, double-masked, active-controlled phase 2 clinical study (NCT05403749)—one of two phase 2 studies conducted on wet AMD in a combined total of 360+ … 8 мая 2025 г. · The Phase 2 trial (NCT05403749) enrolled 132 subjects, randomized 1:1:1 to receive: • IBI302 6.4 mg • IBI302 8.0 mg • Aflibercept 2.0 mg (control) The primary endpoint was the change in … 20 мая 2022 г. · ICH GCP US Clinical Trials Registry Clinical Trial NCT05403749 A Study of Longer Interval of IVT IBI302 in Subjects With nAMD June 26, 2024 updated by: Innovent Biologics … 1 янв. 2026 г. · Protocols were approved by the institutional review board or independent ethics committee at each site. All patients provided written informed consent before the initiation of any … 22 мар. 2024 г. · Innovent phase 2 wet AMD treatment trial meets primary endpoint Key Takeaways Patients with wet AMD experienced visual benefits and anatomic improvements in a phase 2 clinical … Phase 2 Completed Conditions Neovascular Age-related Macular Degeneration Interventions Biological: dose 2 IBI302 Biological: dose 1 IBI302 Drug: Aflibercept Feedback Registration Number … Trial | NCT05403749 Report issue participants: Study Overview Title A Study of Longer Interval of IVT IBI302 in Subjects With nAMD Official Title 6 мая 2025 г. · The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment … 22 дек. 2023 г. · The efficacy and safety of efdamrofusp alfa will be evaluated in an ongoing phase II trial (NCT05403749) and a phase III trial (NCT05972473) with a larger sample size and longer follow …
